CSL secures global rights to Alentis Therapeutics' lixudebart in a deal worth up to US$1.55 billion, marking a major expansion of its rare disease portfolio and clinical pipeline.
CSL has entered into a strategic global partnership with Alentis Therapeutics to develop and commercialize lixudebart, a move that strengthens CSL's rare disease portfolio. The agreement involves a significant upfront payment and potential milestone payments, with both companies agreeing to share global profits, reflecting CSL's commitment to expanding its therapeutic pipeline.
It is a global partnership to develop and commercialize lixudebart with shared global profits.
Alentis Therapeutics has secured a major financial windfall through its partnership with CSL, receiving a US$355 million upfront payment. The deal includes up to US$1.2 billion in potential milestone payments, providing the company with substantial capital to validate its pipeline and fund future research and development.
Alentis receives US$355 million upfront and up to US$1.2 billion in milestone payments.
CSL Limited has entered a strategic global partnership with Swiss-based Alentis Therapeutics to develop and commercialize the drug candidate lixudebart. The deal includes a US$355 million upfront payment and up to US$1.2 billion in potential milestone payments, significantly bolstering CSL's rare disease pipeline.
The deal involves an upfront payment of US$355 million from CSL to Alentis, with additional performance-based milestone payments reaching up to US$1.2 billion.
The partnership focuses on the development and commercialization of lixudebart, a drug candidate aimed at treating rare diseases.